Cyclosporine as primary therapy for A-matched living related donor kidney graft recipients.
Between 1981-87, 48 HLA identical sibling graft recipients were allocated to one of three treatment groups: Group I-15 patients Aza and Pred; Group II-12 CyA alone; Group III-21 CyA and steroids. Only one patient died from a fatal hereditary disease. Graft survival was 100% at one year in all groups and at three years was 86% for Aza, 94% for CyA alone and 100% for CyA and steroids. Rejection episodes occurred in 50% of Aza patients versus 18% in the CyA groups. However 55% of CyA patients require anti-hypertensives versus 20% of Aza recipients, and 12% of CyA patients were switched because of drug toxicity. In a previous study of 36 Aza treated A-matched patients, five of eight losses occurred after the first 5 years--most related to long term effects of immunosuppression. We may have to wait for longer follow-up before drawing conclusions regarding the use of CyA in identically matched living related recipients.
MacDonald
A S
AS
Transplant Service, Dalhousie University, Victoria General Hospital, Halifax, Nova Scotia, Canada.
Belitsky
P
P
Bitter-Suermann
H
H
Cohen
A
A
D000017:ABO Blood-Group System; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*; D014019:Tissue Donors
D000017:ABO Blood-Group System; D003524:Cyclosporins; D006680:HLA Antigens; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone